Filtered By:
Source: Orvosi Hetilap
Condition: Heart Attack
Drug: Actos
This page shows you your search results in order of date.
Order by Relevance | Date
Total 6 results found since Jan 2013.
Rediscovery of pioglitazone
Orv Hetil. 2023 Jul 2;164(26):1012-1019. doi: 10.1556/650.2023.32783. Print 2023 Jul 2.ABSTRACTIn the past decade and a half, clinical diabetology has undergone enormous development. New drug classes have appeared in everyday practice (GLP1 receptor agonists, SGLT2 inhibitors), which are able to improve the outcome of cardiovascular (macrovascular) complications in diabetes within a few years or even a few months, in contrast to the drugs used in previous large, prospective studies (UKPDS, VADT). The use of thiazolidinediones (including pioglitazone) unfortunately and significantly has declined in recent years, both intern...
Source: Orvosi Hetilap - July 2, 2023 Category: General Medicine Authors: Bence Pokoly Anik รณ Somogyi Source Type: research
